Imugene Ltd has released a press release.
First Patient Dosed in VAXINIA Intravenous Cohort 2
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
- Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
- Imugene onCARlytics with blinatumomab SITC presentation
- Europe Patent granted for iNKT Cell Therapy Platform
- First patient dosed in VAXINIA intratumoral cohort 2
Later from Imugene
- CHECKVacc Data Presented at the 2022 SABC Symposium
- Imugene Receives Vaxinia Ethics Approval in Australia
- Imugene VAXINIA trial advances to Combination Cohort
- Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
- First Patients Dosed in Combination Study of VAXINIA
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene